In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The new functionality complements Parse’s existing Evercode immune products
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
The partnership initially will focus on cardiovascular and kidney diseases
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Subscribe To Our Newsletter & Stay Updated
